Your Shopping Cart is empty.
{{ (item.variation.media ? item.variation.media.alt_translations : item.product.cover_media.alt_translations) | translateModel }} {{ (item.variation.media
                    ? item.variation.media.alt_translations
                    : item.product.cover_media.alt_translations) | translateModel
                }}
{{ 'product.bundled_products.label' | translate }}
{{ 'product.bundle_group_products.label' | translate }}
{{ 'product.buyandget.label' | translate }}
{{ 'product.gift.label' | translate }}
{{ 'product.addon_products.label' | translate }}
{{item.product.title_translations|translateModel}}
{{ field.name_translations | translateModel }}
  • {{ childProduct.title_translations | translateModel }}

    {{ getChildVariationShorthand(childProduct.child_variation) }}

  • {{ getSelectedItemDetail(selectedChildProduct, item).childProductName }} x {{ selectedChildProduct.quantity || 1 }}

    {{ getSelectedItemDetail(selectedChildProduct, item).childVariationName }}

{{item.variation.name}}
{{item.quantity}}x NT$0 {{ item.unit_point }} Point
{{addonItem.product.cover_media.alt_translations | translateModel}}
{{ 'product.addon_products.label' | translate }}
{{addonItem.product.title_translations|translateModel}}
{{addonItem.quantity}}x {{ mainConfig.merchantData.base_currency.alternate_symbol + "0" }}

Board of Directors

 

According to the Article of Incorporation, the Company shall elect 5-7 directors and the term shall be three years. The 7th Board of Directors , which consists of 7 directors (including 3 independent directors), has been elected at the Annual General Shareholders' meeting held on June 21, 2021. 

 

Title Name Education & Experience
Chairman (Representative) Dr. Wu Investment Holding Co., Ltd.
Representative:Eric Wu
  • Columbia University, School of Engineering and Applied Science
  • DR.WU Skincare Co., LTd. General Manager
  • PricewaterhouseCoopers LLP, Senior Financial Analyst
Director (Representative) YING-CHIN WU
  • National Taiwan University School of Hospital
  • Clinical Professor of National Taiwan University Hospital (NTUH)
  • Founder and Chief Physician of WCLINIC and WSPA
Director (Representative) Dong Lin Biomedical Co., Ltd.
Representative:Tiger Hsing
  • Department of Accounting NDHU
  • DR.WU Skincare Co.,LTD. Associate Audit Manager
  • Liyu Technology Co.,Ltd. Auditing manager
  • King's Ground Biotech Co.,Ltd. Accounting specialist
  • Ernest Young Limited. Auditing leader
Director (Representative) Dong Ai Investment Co., Ltd.
Representative:Tina Lin
  • Master of Finance, University of Rochester
  • CFO and Spokesperson of Dr. Wu Skincare Co., Ltd
  • Finance Manager and Acting Spokesperson of Eslite Spectrum Corporation
Independent Director Yuan-Jen Hsu
  • University of Pennsylvania-The Wharton School
  • Columbia University Bachelor of Science
  • CEO of Yuan Jen Enterprises
  • Vice Chairman of Hua Nan Securities Co., Ltd.
Independent Director Ching- Yee Lee
  • HITOTSUBASHI UNIVERSITY MBA
  • Global Brands Group, Chief Restructuring Officer
  • Branded Lifestyle Holdings Limited, Director
  • KT Licensing Limited, President / CEO
  • Branded Lifestyle Enterprises Limited Taiwan Branch, CEO
Independent Director Chao-Sheng Chiang
  • National Taipei University Department of Law, Doctor
  • Associate Professor of Department of Law National Chung-Cheng University
  • Secretary General of Taiwan Law Society of Enterprise
  • Assistant Professor of Tunghai University the College of Law
  • CEO of Corporate Legal Research Center

 

董事會績效評估

本公司每年應至少執行一次內部董事會績效評估,評估之範圍包括整體董事會、個別董事成員及功能性委員會之績效評估,評估之方式包括董事會內部自評、董事成員自評或其他適當方式進行績效評估。董事會績效評估之衡量項目包含:對公司營運之參與程度、提升董事會決策品質、董事會組成與結構、董事之選任及持續進修以及內部控制等五大面向;董事成員績效評估之衡量包含:對公司目標與任務之掌握、董事職責認知、對公司營運之參與程度、內部關係經營與溝通、董事之專業及持續進修、內部控制、董事會之運作等七大面向;功能性委員會績效評估之衡量項目包含:對公司營運之參與程度、提升功能性委員會決策品質、功能性委員會組成與結構、內部控制等五大面向。本公司於年度結束後進行內部董事會績效評估,並於第一季提報董事會報告績效評估結果。

本公司2020年度之董事會、功能性委員會之績效評估由公司治理小組執行,採用內部問卷自評方式,評估標準如上述衡量項目及問卷內容所示。於2021年3月董事會提報績效評估結果:各績效考核項目皆符合設定指標,顯示董事會及功能性委員會運作效率良好。

Major Resolutions of Board Meetings

 

 

Year Session Meeting Date Important Resolutions
2022 8-6 05.11
  • Approved the 2022 Q1 Surplus Earnings Distribution.
2022 8-5 03.09
  • Approved the 2021 compensation distribution plan for employees and directors about the amount and form.
  • Approved Business Report and Financial Statements of 2021.
  • Approved the 2021 Surplus Earnings Distribution.
  • Approved the 2021 Statement on Internal Control System.
  • Approved the 2022 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2021 8-4 12.22
  • Approved the 2022 annual budget.
2021 8-3 11.11
  • Approved the 2021 Q3 Surplus Earnings Distribution.
2021 8-2 08.11
  • Approved the 2021 Q2 Surplus Earnings Distribution.
2021 8-1 07.07
  • Approved the election of the chairman.
  • Approved the appointment of the members of the 4th Compensation Committee.
  • Approved to sign a contract with National Chung Cheng University for industry-academic cooperation and academic feedback mechanism.
2021 7-21 06.17
  • Approved the postponed 2021 Shareholders’ meeting date and place due to the Pandemic.
2021 7-20 05.07
  • Approved the 2021 Q1 Surplus Earnings Distribution.
  • Approved the resolution cash distributed from capital surplus to shareholders
2021 7-19 03.05
  • Approved the 2020 compensation distribution plan for employees and directors about the amount and form.
  • Approved Business Report and Financial Statements of 2020.
  • Approved the 2020 Surplus Earnings Distribution.
  • Approved the 2020 Statement on Internal Control System.
  • Approved the 2021 Shareholders’meeting date, place, agenda and proposal
  • Approved the 2021 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2020 7-18 12.18
  • Approved the 2021 annual budget.
2020 7-17 11.10
  • Approved subsidiary Wclinic Biotechnology Corporation(Samoa) disposal of shares in Jiangsu DR. WU Cosmetics Co., Ltd.
2020 7-16 11.06
  • Approved the 2020 Q3 Surplus Earnings Distribution.
2020 7-15 10.23
  • Approved subsidiary Wclinic Biotechnology Corporation, it plans to invest in the establishment of an overseas BVI subsidiary.
2020 7-14 08.07
  • Approved the 2020 Q2 Surplus Earnings Distribution.
2020 7-13 05.06
  • Approved the 2020 Q1 Surplus Earnings Distribution.
2020 7-12 03.13
  • Approved the 2019 compensation distribution plan for employees and directors about the amount and form.
  • Approved Business Report and Financial Statements of 2019.
  • Approved the 2019 Surplus Earnings Distribution.
  • Approved the 2019 Statement on Internal Control System.
  • Approved the 2020 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2019 7-11 12.24
  • Approved the 2020 annual budget.
  • Approved the 2020 auditing plans for the Company and its subsidiary.
  • Approved the 2019 evaluation of the CPA’s independence and suitability.
  • Approved the resolution cash distributed from capital surplus to shareholders.
  • Approved the amendment to “Articles of Incorporation.
  • Approved the 2020 First extraordinary general meeting date and place.
2019 7-10 11.07
  • Reported the third quarter 2019 consolidated financial statements.
  • Approved the subsidiary Wclinic Biotechnology capital reduction to cover losses.
2019 7-9 08.06
  • Reported the second quarter 2019 consolidated financial statements.
  • Approved the amendment to the "Operational Procedures for Loaning of Company Funds.
  • Approved the amendment to the "Operational Procedures for Endorsements and Guarantees.
  • Approved the amendment to the "Policies and systems for compensation of the directors and functional committees.
  • Approved the subsidiary Wclinic Biotechnology capital reduction to cover losses.
  • Approved the subsidiary Wclinic Biotechnology capital reduction and return to parent company.
2019 7-8 05.09
  • Reported the first quarter 2019 consolidated financial statements.
  • Approved the appointment of managers.
2019 7-7 02.26
  • Approved the 2018 compensation distribution plan for employees and directors about the amount and form.
  • Approved Business Report and Financial Statements of 2018.
  • Approved the 2018 Deficit Compensated.
  • Approved the 2018 Statement on Internal Control System.
  • Approved the amendment to the Operational Procedures for Acquisition and Disposal of Assets.
  • Approved the change of business place of the Company.
  • Approved the 2019 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
  • Approved the resolution cash distributed from capital surplus to shareholders.
2018 7-6 12.24
  • Approved the investment of Dr. Wu Skincare (Jiangsu) Co., Ltd.
  • Approved the equity disposal of Dr. Wu Skincare (Shanghai) Co., Ltd.
2018 7-5 12.13
  • Approved the 2019 annual budget.
  • Approved the 2019 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
  • Approved the 2018 evaluation of the CPA’s independence and suitability.
2018 7-4 11.08
  • Approved the application for Complaint Procedures.
  • Approved the accounts receivable are restated as other accounts receivable considered as fund loaning.
  • Approved the compensation for the CFO.
2018 7-3 09.20
  • Approved the increase in capital for Dr. Wu Skincare (Shanghai) Co., Ltd.
2018 7-2 08.13
  • Approved the appointment members of the third session of compensation committee.
  • Approved the accounts receivable are restated as other accounts receivable considered as fund loaning.
2018 7-1 06.21
  • Approved Mr. Eric Wu as Chairman.
2018 6-22 05.10
  • Approved the appointment of the CFO.
  • Approved the appointment of the Internal Audit Manager.
  • Approved the record date of capital reduction for the cancellation of treasury shares.
  • Approved the accounts receivable-related party are restated as other accounts receivable.
  • Approved the submission of examination of nominated directors (including independent directors) candidate list to board of directors.
  • Approved the exemption from non-compete clause for new directors (including independent directors).
2018 6-21 03.08
  • Approved the 2017 compensation distribution plan for employees and directors about the amount and form.
  • Approved Business Report and Financial Statements of 2017.
  • Approved the 2017 Surplus Earnings Distribution.
  • Approved the 2017 Statement on Internal Control System.
  • Approved the loan to the Company’s subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
  • Approved the accounts receivable-related party are restated as other accounts receivable, shall be recognized as fund loaning.
  • Approved the re-elections of directors (inculding independent directors).
  • Approved the propose of candidates for directors (including independent directors) to be nominated by the Board of Directors.
  • Approved the 2018 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2018 6-20 01.10
  • Approved the repurchasing of Company’s stocks.
2017 6-19 12.14
  • Approved the 2018 annual budget.
  • Approved the 2018 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
  • Approved the 2017 evaluation of the CPA’s independence and suitability.
2017 6-18 11.09
  • Reported the Third quarter 2017 consolidated financial statements.
  • Approved the amendments to Audit Committee Charter、Rules of Procedure for Board of Directors Meetings and Rules Governing the Scope of Powers of Independent Directors.
  • Approved the Company’s subsidiary Dr.Wu Skincare (Shanghai) Co., Ltd. investment to set up subsidiary.
2017 6-17 08.10
  • Reported the second quarter 2017 consolidated financial statements.
  • Approved the change of business place of the Company.
2017 6-16 03.10
  • Approved the Company’s ex-dividend-date.
  • Approved the appointment of a deputy G.M.
2017 6-15 03.10
  • Reported the first quarter 2017 consolidated financial statements.
  • Approved the evaluation of the list of nominated candidates for directors to the Board.
  • Approved the 2016 compensation distribution plan for managers.
2017 6-14 03.10
  • Approved the 2016 compensation distribution plan for employees and directors about the amount and form.
  • Approved Business Report and Financial Statements of 2016.
  • Approved the 2016 Surplus Earnings Distribution.
  • Approved the 2016 Statement on Internal Control System.
  • Approved the amendments to the Settlement Procedures for the Acquisition and Disposal of Assets.
  • Approved the loan to the Company’s subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
  • Approved the Company’s cooperation with Price Waterhouse Coopers (PwC) Taiwan for auditor rotation.
  • Approved the by-election of one director and the proposed candidates for directors to be nominated by the Board of Directors.
  • Approved the 2017 Shareholders’meeting date, place, agenda and proposal made by shareholders with over 1% share.
2016 6-13 12.19
  • Approved the 2017 annual budget.
  • Approved the 2016 auditing plans for the Company and its mainland subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
  • Approved the 2016 evaluation of the CPA’s independence and suitability.
  • Approved the appointment of the CFO.
  • Approved the compensation for the CFO.
2016 6-12 11.07
  • Reported the third quarter 2016 consolidated financial statements.
  • Approved the increase in capital for Dr. Wu Skincare (Shanghai) Co., Ltd.
2016 6-11 08.08
  • Reported the second quarter 2016 consolidated financial statements.
2016 6-10 05.20
  • Approved the appointment of a deputy financial director.
2016 6-9 05.12
  • Approved the Company’s ex-rights date, ex-dividend-date and capital increase date.
  • Approved the appointment of managers.
  • Approved the compensation for managers.
  • Approved the 2015 compensation distribution plan for managers.
  • Approved the issuance of new shares through cash distribution to managers before listing on the OTC market.
2016 6-8 03.07
  • Approved the 2015 compensation distribution plan (i.e. amount and form) for employees and directors.
  • Approved the 2015 Business Report and Financial Statements.
  • Approved the 2015 Statement on Internal Control System.
  • Approved the 2015 Surplus Earnings Distribution.
  • Approved the Issuance of New Common Shares for Capital Increase through Retained Earnings.
  • Approved the Issuance of New Common Shares for Capital Increase through Cash.
  • Approved the change of CFO and spokesperson.
  • Approved the loan to subsidiary Dr. Wu Skincare (Shanghai) Co., Ltd.
  • Approved the application for suspension and resumption of trading procedures.
  • Approved the new agenda and amendments to the 2016 Shareholders’ Meeting.
2016 6-7 01.21
  • Approved the 2016 Shareholders’ meeting date, place, agenda and proposal made by shareholders with over 1% share.